Scott Skibo, MD currently serves as the Chief Medical Officer for Eon Health.  Prior to joining Eon Health in 2021, he has presented regularly at national scientific meetings focused on interventional pulmonology and lung cancer.  After finishing his pulmonary and critical care fellowship at Yale University in 2001, he gained over 20 years of experience in the thoracic oncology clinical space.  He co-developed the first system-wide incidental pulmonary nodule program in the United States in 2012.  He now leads the clinical team at Eon that oversees the quality and clinical outcomes for over 1000 US-based hospitals- helping to ensure the timely care for over 1 million patients per year.

Layah Liz Jacob is a PhD Scholar at CHRIST (Deemed to be University), Bengaluru, India under the guidance of Dr. Anuradha S. She holds an M.Sc in Clinical psychology from the same university and has been actively involved in the field of women and trauma for over 6 years. Alongside her supervisor, she was also a part of a collaborative research project with Miami university, focusing on enhancing life after cancer survivorship. Her doctoral research explores the interplay of existentialism, mortality awareness and spirituality in fostering post traumatic growth among cancer survivors, aiming to deepen understanding and support for their psychological recovery

Sanju Mannumadam Venugopal is based out of California, USA. He is working as Senior Manager at a decentralized clinical trial technology company. Has a bachelor’s degree in Bioinformatics and an MBA in Information Systems. Has 13+ years’ of experience in Technology & Compliance in healthcare and pharmaceutical domain. He is an independent researcher in artificial intelligence (AI) and healthcare. Has published research papers in various journals on topics such as AI in oncology medical image analysis, generative AI in healthcare, responsible AI in healthcare etc. He is an active member of IEEE working on standards for developing LLM Agentic AI interface. He is a member of ISPE. He has reviewed paper in reputed journal such as “Expert System” related to medical AI research. He is an Elsevier-certified peer reviewer.

Janusz Rak, MD, PhD is a Professor of Pediatrics and Jack Cole Chair in Pediatric Hematology/Oncology at McGill University, Investigator at the Research Institute of the McGill University Health Centre (RIMUHC), and Fellow of the Royal Society of Canada. His laboratory investigates how oncogenic events deregulate tumour microenvironment, orchestrate intercellular communication and trigger vascular alterations and systemic vascular paraneoplastic syndromes in cancer. The focal point of these studies are processes mediated by the exchange of extracellular vesicles (EVs), including exosomes, heterogeneous carriers of oncogenic, diagnostic and therapeutic cargo. This work is encapsulated in 220 research papers (45,000 citations).

Bosede O. Adebayo-Oke is a registered dietitian nutritionist and clinical psychologist with over 20 years of clinical nursing experience. She earned a PhD in Clinical Psychology, an MSc in Human Nutrition and Dietetics, and a Master's in Counselling Psychology from the University of Ibadan, Nigeria. Currently, she is a lecturer in Human Nutrition and Dietetics, with research centered on nutritional counselling, dietary modifications, behavioural change, and quality of life improvement through clinical nutrition interventions, particularly for oncology patients. She actively contributes to teaching, research, and community nutrition education in Southwest Nigeria, advancing health outcomes through multidisciplinary approaches.

Formerly Consultant Breast Surgeon at Imperial College Healthcare Trust ( at Charing Cross Hospital 2006 -2014 ) London SW6 .Previously Consultant Breast Surgeon  at Royal Marsden Hospital ,Fulham Road, London SW3.

Hisham Khalifa is an Assistant Professor of Surgical Oncology at the National Cancer Institute (NCI) of Cairo University and a Senior Consultant in the Gynecologic Oncology Department. In addition to clinical and academic duties at the NCI, he leads and oversees the Gynecologic Oncology Department at Shefaa Elorman Hospital in Luxor, Egypt.

Tao Peng is an Associate Chief Physician of Traditional Chinese Medicine and serves as the Director of the Fourth Department of Oncology at Shenzhen Hospital of Guangzhou University of Chinese Medicine. He holds a doctoral degree and holds the academic title of Associate Professor. A graduate of Zhejiang Chinese Medical University, Dr. Peng has been dedicated to the field of TCM oncology for more than a decade. He possesses extensive experience in the integrated TCM-Western medicine diagnosis and treatment of common malignancies, including lung cancer, breast cancer, colorectal cancer, gastric cancer, and liver cancer.

Lijuan Ye is a professor in Yan'an Hospital Affiliated of Kunming Medical University, China. Has 18 years’ experience as an pathologist. I regularly publishes in the molecular and pathological literature, and regularly presents data at national and international scientifice meetings. Our group has conducted a comprehensive study on the role of non-coding RNA in lung adenocarcinoma and developed a diagnostic kit in preparation to applying this technology clinically.

Yu Aoki is a staff member in the Department of Medical Oncology at Tokyo Saiseikai Central Hospital and a visiting trainee in the Department of Gastrointestinal Oncology, National Cancer Center Hospital East, Japan. She has 14 years of clinical experience as an oncologist and has authored several publications related to clinical research in gastrointestinal cancers. 

Xiao Meng, MD, Associate Professor, Associate Chief Physician, Master's Supervisor. She is engaged in research on lymphoma and the tumor immune microenvironment. She has presided over or participated in multiple provincial and municipal research projects, and her achievements have been selected for poster presentations at international conferences, with invitations for oral reports. She is a member of the Hematology Committee of Shandong Geriatric Medical Association, a member of the Hematology Committee of Shandong Association of Integrated Traditional Chinese and Western Medicine, and a member of the Hematology Branch of Jining Medical Association.

Shikha Bose is Professor of Pathology at Cedar~Sinai Medical Center and at the David Geffen School of Medicine, University of California, Los Angeles. She has authored more than 130 peer-reviewed scientific articles and has been an invited speaker at many national and international meetings. She has been involved in several NIH-sponsored studies. She is a member of the College of American Pathologists Breast Cancer Protocol Review Panel and the American Joint Committee on Cancer - Breast Cancer Staging System and helped formulate the recommendations for breast cancer staging and diagnosis. Dr. Bose was the Director of cytopathology for 22 years. 

Juliana Namutundu is an Assistant Lecturer at Makerere University School of Public Health, Uganda. Her area of professional and research interest is health services research, specifically addressing disparities in access to health services, quality of healthcare, economic evaluations, and implementation research. She has participated in various research studies in these areas. She conducted research addressing disparities in access to cervical cancer screening services among rural women living with HIV in Eastern Uganda. This research engaged rural women living with HIV and healthcare providers in identifying, selecting, designing, and evaluating strategies for improving cervical cancer screening literacy among these women. 

Harald Stein is a former Director of the Institute of Pathology at the Free University of Berlin and Charité. He served as an editor of the WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues in 2001, 2008, and 2017. He is credited with the discovery of the molecules CD30 and Ki-67, as well as the characterization of anaplastic large cell lymphoma (ALCL). Over the course of his career, he has published more than 800 scientific articles on lymphomas.In 1989–1990, together with Professor Peter Isaacson (England), he co-founded the International Lymphoma Study Group (ILSG) to resolve longstanding differences in lymphoma classification between the United States and Europe. This effort culminated in 1994 with the development of a biologically sound and clinically relevant system known as the REAL (Revised European-American Lymphoma) classification, which successfully helped end the transatlantic classification dispute.

Sayem Shezad is a 4th Year medical student at University College London, with a Bachelor of science in Oncology (first class honours). Aspiring toward a career in oncology, has completed research involving cancer clinical trial efficacy and accesibility in london, as well as osteosarcoma cell usage for bone formation. This work was a part of a wider project under the UCL cancer institute, would be honoured to present to the oncology community.

Dr Ali Abougazia is a Consultant Radiologist at University Hospitals of Derby and Burton NHS Foundation Trust, UK. He has over 14 years of experience in clinical radiology, with Special interest in breast cancer imaging. He is a Fellow of the Royal College of Radiologists (FRCR) and holds a Master’s degree in clinical Radiology. Dr. Abougazia is research active, and presents his work at local, national and international scientific meetings. His research focuses on advancing the diagnosis of breast cancer using traditional and innovative imaging techniques

Wukui Huang has the position of chief physician at the Auxiliary Cancer Hospital of Xinjiang Medical University. He has 16 years of experience in interventional radiology at Xinjiang Medical University. He frequently publishes papers in the fields of interventional radiology and oncology. His team retrospectively analyzed data from patients with cervical cancer and vaginal bleeding, and proposed that pelvic artery embolization can be an effective treatment for locally advanced cervical cancer with vaginal bleeding, which is more effective and long-lasting than traditional vaginal tamponade hemostasis therapy.

Dr. Yuanyuan Wang is an attending physician and medical doctor at the First Affiliated Hospital of Henan Medical University, China. With more than 10 years of experience in gynecologic oncology, she has long been engaged in clinical and basic research on gynecologic malignancies, focusing on the precision diagnosis and treatment of endometrial cancer and cervical cancer, and is skilled in minimally invasive gynecologic surgery. She holds several academic appointments including Youth Member of the Gynecologic Oncology Committee of Henan Province. She has participated in multiple provincial and ministerial research projects and published numerous academic papers as the first author in domestic and international journals. At this conference, she will present her latest findings and share advances in gynecologic oncology practice.

Irma Shamatava earned her Ph.D. in Electrical and Electronics Engineering from Tbilisi State University (TSU) in 2015. Her research interests include magnetic nanoparticle hyperthermia for deep tissue cancer treatment. She is a member of both the Dartmouth Electromagnetic Sensing Group and the TSU team, where she contributes to experiment design, modeling, and optimization of magnetic nanoparticle hyperthermia treatment methodologies for clinical applications. She has presented her work at the Society of Thermal Medicine Conference annual meetings.

Prof.Iris Manor-Binyamini is an Associate Professor in the Department of Social Work at Tel-Hai University, Israel. One of her research areas focuses on psycho-oncology, cancer survivorship, and the psychosocial experiences of culturally diverse and underserved populations. Drawing on qualitative and mixed-methods approaches, she examines how cultural, familial, and social contexts shape coping, well-being, and healthcare experiences among individuals facing serious illness and disabilities. Her recent work has focused on breast cancer survivorship among Bedouin women, highlighting the role of family support, body image, and culturally responsive psychosocial care in promoting well-being within minority communities.

Scott Skibo, MD currently serves as the Chief Medical Officer for Eon Health.  Prior to joining Eon Health in 2021, he has presented regularly at national scientific meetings focused on interventional pulmonology and lung cancer.  After finishing his pulmonary and critical care fellowship at Yale University in 2001, he gained over 20 years of experience in the thoracic oncology clinical space.  He co-developed the first system-wide incidental pulmonary nodule program in the United States in 2012.  He now leads the clinical team at Eon that oversees the quality and clinical outcomes for over 1000 US-based hospitals- helping to ensure the timely care for over 1 million patients per year.

Janusz Rak, MD, PhD is a Professor of Pediatrics and Jack Cole Chair in Pediatric Hematology/Oncology at McGill University, Investigator at the Research Institute of the McGill University Health Centre (RIMUHC), and Fellow of the Royal Society of Canada. His laboratory investigates how oncogenic events deregulate tumour microenvironment, orchestrate intercellular communication and trigger vascular alterations and systemic vascular paraneoplastic syndromes in cancer. The focal point of these studies are processes mediated by the exchange of extracellular vesicles (EVs), including exosomes, heterogeneous carriers of oncogenic, diagnostic and therapeutic cargo. This work is encapsulated in 220 research papers (45,000 citations).

Harald Stein is a former Director of the Institute of Pathology at the Free University of Berlin and Charité. He served as an editor of the WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues in 2001, 2008, and 2017. He is credited with the discovery of the molecules CD30 and Ki-67, as well as the characterization of anaplastic large cell lymphoma (ALCL). Over the course of his career, he has published more than 800 scientific articles on lymphomas.In 1989–1990, together with Professor Peter Isaacson (England), he co-founded the International Lymphoma Study Group (ILSG) to resolve longstanding differences in lymphoma classification between the United States and Europe. This effort culminated in 1994 with the development of a biologically sound and clinically relevant system known as the REAL (Revised European-American Lymphoma) classification, which successfully helped end the transatlantic classification dispute.